Aptose Biosciences Inc. (APTO) CEO William G. Rice Buys 10,000 Shares
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice bought 10,000 shares of Aptose Biosciences stock in a transaction dated Thursday, April 18th. The stock was acquired at an average price of $1.85 per share, with a total value of $18,500.00. Following the completion of the transaction, the chief executive officer now directly owns 153,014 shares of the company’s stock, valued at $283,075.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Aptose Biosciences stock opened at $1.83 on Friday. Aptose Biosciences Inc. has a 52-week low of $1.57 and a 52-week high of $4.55. The company has a market capitalization of $73.66 million, a P/E ratio of -2.13 and a beta of 1.61.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). As a group, equities research analysts forecast that Aptose Biosciences Inc. will post -0.72 EPS for the current fiscal year.
Several equities research analysts recently issued reports on APTO shares. Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. HC Wainwright set a $9.00 price objective on shares of Aptose Biosciences and gave the company a “buy” rating in a research note on Friday, March 22nd. Citigroup initiated coverage on shares of Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price objective for the company. Oppenheimer initiated coverage on shares of Aptose Biosciences in a research note on Thursday, January 24th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Royal Bank of Canada initiated coverage on shares of Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Aptose Biosciences presently has an average rating of “Buy” and a consensus target price of $5.71.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.mareainformativa.com/news/2019/04/20/aptose-biosciences-inc-apto-ceo-william-g-rice-buys-10000-shares.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.